Viral rebound common in lung transplant recipients treated with nirmatrelvir/ritonavir for COVID-19 Post author: Post published:October 24, 2023 Post category:uncategorized Data on the viral rebound and safety of nirmatrelvir/ritonavir in lung transplant (LTx) recipients are limited. You Might Also Like Deep-learning tissue clocks reveal how organs age and leave disease-linked signals in blood August 18, 2026 Decoding how the brain understands sentences in real-time October 29, 2023 Research uncovers Blautia bacteria’s crucial role in gut health and disease protection April 29, 2024
Deep-learning tissue clocks reveal how organs age and leave disease-linked signals in blood August 18, 2026
Research uncovers Blautia bacteria’s crucial role in gut health and disease protection April 29, 2024